Welcome to Francis Academic Press

Academic Journal of Medicine & Health Sciences, 2023, 4(1); doi: 10.25236/AJMHS.2023.040108.

Research progress of Mu Xiang in the treatment of ulcerative colitis


Jia Lingna1, Hui Jianping2, Li Xinyi1, Zhang Huayi1

Corresponding Author:
Hui Jianping

1Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China

2Department of Spleen and Gastroenterology, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, China


Ulcerative colitis is an inflammatory bowel disease characterized by recurrent episodes of intestinal mucosal inflammation, with three major clinical manifestations: abdominal pain, diarrhea, and posterior urgency. The pathogenesis is still unclear, therefore, treatment is also based on anti-inflammatory and other symptomatic support. With the rapid development of Traditional Chinese medicine, Chinese herbal medicine plays an important role in the treatment of ulcerative colitis. This paper presents a review of Mu Xiang, a Chinese herbal medicine, in the treatment of ulcerative colitis.


ulcerative colitis, pathogenesis, immune regulation, anti-inflammatory, antioxidant

Cite This Paper

Jia Lingna, Hui Jianping, Li Xinyi, Zhang Huayi. Research progress of Mu Xiang in the treatment of ulcerative colitis. Academic Journal of Medicine & Health Sciences (2023) Vol. 4, Issue 1: 45-50. https://doi.org/10.25236/AJMHS.2023.040108.


[1] Eisenstein M. Ulcerative colitis: towards remission[J]. Nature, 2018, 563(7730): S33-S33.

[2] 2Kirsner J B. The local and systemic complications of inflammatory bowel disease[J]. Jama, 1979, 242(11): 1177-1183. 

[3] Du L, Ha C. Epidemiology and pathogenesis of ulcerative colitis[J]. Gastroenterology Clinics, 2020, 49(4): 643-654. 

[4] Cosnes J, Gower–Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases[J]. Gastroenterology, 2011, 140(6): 1785-1794. e4.

[5] Yang Qianqian, Zhou Jianbo, Cai Sheng, et al.Feasibility analysis on the efficacy and adverse reactions of azathioprine in the treatment of ulcerative colitis and Crohn's disease [J]. Chinese Journal of Medicine and Clinical Medicine, 2018, 18 (10): 1739-1741

[6] An Yuqiu, Wang Huijuan. Research on the rule of drug use in active stage of ulcerative colitis based on data mining [J]. Shandong Journal of Traditional Chinese Medicine, 2022, 41 (07): 721-726. DOI: 10.16295/j.cnki.0257-358x.2022.07.005

[7] Xavier R J, Podolsky D K. Unravelling the pathogenesis of inflammatory bowel disease[J]. Nature, 2007, 448(7152): 427-434.

[8] Jewell D P, Sutherland L R, McDonald J W D, et al. Ulcerative colitis[J]. Evidence‐based Gastroenterology and Hepatology, 2010: 232-247. 

[9] Jostins L, Ripke S, Weersma R K, et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease[J]. Nature, 2012, 491(7422): 119-124. 

[10] Lees C W, Barrett J C, Parkes M, et al. New IBD genetics: common pathways with other diseases[J]. Gut, 2011, 60(12): 1739-1753. 

[11] de Lange K M, Barrett J C. Understanding inflammatory bowel disease via immunogenetics[J]. Journal of autoimmunity, 2015, 64: 91-100.

[12] Sands BE, Kaplan GG. The role of TNFalpha in ulcerative colitis. J Clin Pharmacol 2007;47:930–41. 

[13] Ordas I, Eckmann L, T alamini M, et al. Ulcerative colitis. Lancet 2012;380:1606–19. 

[14] Zhang FX, Kirschning CJ, Mancinelli R, et al. Bacterial lipopolysaccharide acti-vates nuclear factor-kappaB through interleukin-1 signaling mediators in cultured human dermal endothelial cells and mononuclear phagocytes. J Biol Chem 1999; 274: 7611–4. 

[15] Hart AL, Al-Hassi HO, Rigby RJ, et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 2005;129:50–65 

[16] Heller F, Fromm A, Gitter AH, et al. Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation: effect of pro-inflammatory interleukin-13 on epithelial cell function. Mucosal Immunol 2008;1(Suppl 1):S58–61 

[17] Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhe-sion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151:97–110.

[18] National Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China: A [M] 2020 Edition. Beijing:China Medical Science and Technology Press.2020:266,63.

[19] ZHANG Nanping,YU Kunzi,KANG Shuai,LIAN Chaojie,CHEN Hong,MA Shuangcheng. Study of Muxiang Jiyuan in ancient Materia Medica[J].China Pharmaceutical Affairs,2019,33(02):172-176.DOI:10.16153/j.1002-7777.2019.02.009.)

[20] Zheng Jiamei, Shang Mingyue, Wang Jiale, et al.Chemical constituents, pharmacological effects, clinical application research progress and quality marker prediction of Aucklandia odora [J]. Chinese Herbal Medicine, 2022,53 (13): 4198-4213.

[21] Park E J, Park S W, Kim H J, et al. Dehydrocostuslactone inhibits LPS-induced inflammation by p38MAPKdependent induction of hemeoxygenase-1 in vitro and improves survival of mice in CLP-induced Sepsis in vivo [J]. Int Immunopharmacol, 2014, 22(2): 332-340. 

[22] Lim H S, Ha H, Shin H K, et al. The genome-wide expression profile of Saussurea lappa extract on house dust mite-induced atopic dermatitis in nc/nga mice [J]. Mol Cells, 2015, 38(9): 765-772. 

[23] Seo C S, Lim H S, Jeong S J, et al. Anti-allergic effects of sesquiterpene lactones from the root of Aucklandia lappa Decne [J]. Mol Med Rep, 2015, 12(5): 7789-7795. 

[24] Mohamed A. Evaluation of antimicrobial activity of different solvent extracts of Saussurea lappa [J]. World J Pharm Pharm Sci, 2017: 12-18. 

[25] Li Y, Xu C, Zhang Q, et al. In vitro anti-Helicobacter pylori action of 30 Chinese herbal medicines used to treat ulcer diseases [J]. J Ethnopharmacol, 2005, 98(3): 329- 333. 

[26] Qiu J, Wang J, Luo H, et al. The effects of subinhibitory concentrations of Costus oil on virulence factor production in Staphylococcus aureus [J]. J Appl Microbiol, 2011, 110(1): 333-340. 

[27] Wang Xuying, Jia Xiaobin, Chen Yan Research progress of woody incense [J]. Traditional Chinese Medicine, 2010, 33 (1): 153-157

[28] Zhang Lin, Xiao Yanying, Ma Baohua. Research progress on pharmacological effects of Xianglian Pills [J]. Shaanxi Journal of Traditional Chinese Medicine, 2015,36 (01): 127-128

[29] Qiu Kuan, Xiong Wenwen, Xu Song, et al. Study on the law of prescriptions for dysentery in ancient literature based on data mining [J]. Jiangxi Journal of Traditional Chinese Medicine, 2022,53 (09): 45-49.

[30] Yang Shanshan, Hao Shaodong, Ye Hui, et al. Analysis of the medication law of national patent compound of traditional Chinese medicine for the treatment of peptic ulcer[J]. Shizhen Chinese Medicine and Chinese Medicine,2021,32(05):1269-1271.)

[31] Wang Zhibin, Chen Chen, Guo Yi, et al. Clinical study of Qingchang Wenzhong on mild to moderate ulcerative colitis [J]. Chinese Journal of Integrated Traditional and Western Medicine, 2018, 38 (01): 15-19 

[32] Chen Jieling, Shen Jie, Liu Guozheng Clinical Study on 30 Cases of Ulcerative Colitis Treated by "Yiqi Jiedu Huayu Recipe" Combined with Conventional Western Medicine [J]. Jiangsu Traditional Chinese Medicine, 2021,53 (03): 34-37. DOI: 10.19,844/j.cnki.1X.2021.03.013

[33] Min Y Zhe S, Chao H Y’ et a1. The therapeutic role of oral tolerance in dextran sulfate sodium. induced colitis via Thl-Th2 balance and V6 T cells [J]. Journal of Diges-tive Diseases, 2013, 14(10): 543-551. 

[34] Park E, Song J H, Kim M S, et al. Costunolide, a sesquiterpene lactone, inhibits the differentiation of pro-inflammatory CD4+ T cells through the modulation of mitogenactivated protein kinases[J]. International Immunopharmacology, 2016, 40: 508-516. 

[35] Song Jie, Guo Ruifang, Nie Hong, et al. The effect and mechanism of sasaki lactone on intestinal immune inflammation in mice with ulcerative colitis [J]. Journal of Guangxi Medical University, 2021,38 (12): 2300-2305. DOI: 10.16190/j.cnki.45-1211/r.2021.12.016

[36] Chen Y, Zheng H, Zhang J, et al. Reparative activity of costunolide and dehydrocostus in a mouse model of 5-fluorouracil-induced intestinal mucositis[J]. RSC advances, 2016, 6(7): 5249-5258. 

[37] Koo T H, Lee J H, Park Y J, et al. A sesquiterpene lactone, costunolide, from Magnolia grandiflora inhibits NF-κB by targeting IκB phosphorylation[J]. Planta Medica, 2001, 67(02): 103-107. 

[38] Scarponi, C., Butturini, E., Sestito, R. et al. Inhibition of inflammatory and proliferative responses of human keratinocytes exposed to the sesquiterpene lactones dehydrocostuslactone and costunolide. PLoS ONE 2014, 9, e107904. 

[39] Kang J S, Yoon Y D, Lee K H, et al. Costunolide inhibits interleukin-1β expression by downregulation of AP-1 and MAPK activity in LPS-stimulated RAW 264.7 cells[J]. Biochemical and biophysical research communications, 2004, 313(1): 171-177. 

[40] Rajalakshmi M, Anita R. In vitro and in silico evaluation of antioxidant activity of a sesquiterpene lactone, costunolide, isolated from costus specious rhizome on MCF-7 and MDA-MB-231 human breast cancer cell lines[J]. World J. Pharm. Pharm. Sci, 2014, 3: 1334- 1347. 

[41] Pae, H.-O.; Jeong, G.-S.; Kim, H.-S. et al. Costunolide inhibits production of tumor necrosis factor-α and interleukin-6 by inducing heme oxygenase-1 in RAW264. 7 macrophages. Inflamm. Res. 2007, 56, 520–526.

[42] Xing Liying, Bai Xinglong, Shang Ke, et al. Exploring the mechanism of Huanglian Jiedu Decoction in treating ulcerative colitis based on network pharmacology [J]. China Pharmacoeconomics, 2022,17 (04): 78-82

[43] Wang Jing, Zhong Wei, Zhang Haihua, et al. Research progress on the role and mechanism of TGP in the treatment of ulcerative colitis [J/OL]. Chinese Materia Medica, 2022 (05): 1300-1304 [2022-11-27]. DOI: 10.13863/j.issn1001-4454.2022.05.045.